164 related articles for article (PubMed ID: 24625356)
21. Biomarker targets and novel therapeutics.
Clouser M; Hess LM; Chambers SK
Cancer Treat Res; 2009; 149():85-105. PubMed ID: 19763432
[No Abstract] [Full Text] [Related]
22. Targeting phosphatases of regenerating liver (PRLs) in cancer.
Wei M; Korotkov KV; Blackburn JS
Pharmacol Ther; 2018 Oct; 190():128-138. PubMed ID: 29859177
[TBL] [Abstract][Full Text] [Related]
23. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
24. A screen of FDA-approved drugs identifies inhibitors of protein tyrosine phosphatase 4A3 (PTP4A3 or PRL-3).
Rivas DR; Dela Cerna MVC; Smith CN; Sampathi S; Patty BG; Lee D; Blackburn JS
Sci Rep; 2021 May; 11(1):10302. PubMed ID: 33986418
[TBL] [Abstract][Full Text] [Related]
25. New targets for non-small-cell lung cancer therapy.
Alvarez M; Roman E; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1423-37. PubMed ID: 17944567
[TBL] [Abstract][Full Text] [Related]
26. c-MET kinase inhibitors: a patent review (2011 - 2013).
Zhu K; Kong X; Zhao D; Liang Z; Luo C
Expert Opin Ther Pat; 2014 Feb; 24(2):217-30. PubMed ID: 24266843
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Targeting of Oncogenic Tyrosine Phosphatases.
Frankson R; Yu ZH; Bai Y; Li Q; Zhang RY; Zhang ZY
Cancer Res; 2017 Nov; 77(21):5701-5705. PubMed ID: 28855209
[TBL] [Abstract][Full Text] [Related]
28. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage.
Daouti S; Li WH; Qian H; Huang KS; Holmgren J; Levin W; Reik L; McGady DL; Gillespie P; Perrotta A; Bian H; Reidhaar-Olson JF; Bliss SA; Olivier AR; Sergi JA; Fry D; Danho W; Ritland S; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2008 Feb; 68(4):1162-9. PubMed ID: 18281492
[TBL] [Abstract][Full Text] [Related]
29. Discovery and Evaluation of PRL Trimer Disruptors for Novel Anticancer Agents.
Bai Y; Yu ZH; Zhang ZY
Methods Mol Biol; 2016; 1447():121-38. PubMed ID: 27514804
[TBL] [Abstract][Full Text] [Related]
30. Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.
Zámečníkova A
Expert Opin Drug Discov; 2014 Jan; 9(1):77-92. PubMed ID: 24294890
[TBL] [Abstract][Full Text] [Related]
31. Elucidation of escitalopram oxalate and related antidepressants as putative inhibitors of PTP4A3/PRL-3 protein in hepatocellular carcinoma: A multi-computational investigation.
Mir IH; Shyam KT; Balakrishnan SS; Kumar MS; Ramesh T; Thirunavukkarasu C
Comput Biol Chem; 2024 Jun; 110():108039. PubMed ID: 38471352
[TBL] [Abstract][Full Text] [Related]
32. Strategies for developing protein tyrosine phosphatase inhibitors.
Tautz L; Mustelin T
Methods; 2007 Jul; 42(3):250-60. PubMed ID: 17532512
[TBL] [Abstract][Full Text] [Related]
33. Comparing antibody and small-molecule therapies for cancer.
Imai K; Takaoka A
Nat Rev Cancer; 2006 Sep; 6(9):714-27. PubMed ID: 16929325
[TBL] [Abstract][Full Text] [Related]
34. Diflomotecan. Ipsen.
Osheroff N
IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
[No Abstract] [Full Text] [Related]
35. Synthesis, activity and molecular modeling of a new series of chromones as low molecular weight protein tyrosine phosphatase inhibitors.
Forghieri M; Laggner C; Paoli P; Langer T; Manao G; Camici G; Bondioli L; Prati F; Costantino L
Bioorg Med Chem; 2009 Apr; 17(7):2658-72. PubMed ID: 19297174
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
[TBL] [Abstract][Full Text] [Related]
37. Targeting cancer with small-molecular-weight kinase inhibitors.
Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
[TBL] [Abstract][Full Text] [Related]
38. Discovery of novel drugs for promising targets.
Martell RE; Brooks DG; Wang Y; Wilcoxen K
Clin Ther; 2013 Sep; 35(9):1271-81. PubMed ID: 24054704
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory activities of anthraquinones from Rubia akane on phosphatase regenerating liver-3.
Moon MK; Han YM; Lee YJ; Lee LH; Yang JH; Kwon BM; Kim DK
Arch Pharm Res; 2010 Nov; 33(11):1747-51. PubMed ID: 21116777
[TBL] [Abstract][Full Text] [Related]
40. Structure-based optimization of benzoic acids as inhibitors of protein tyrosine phosphatase 1B and low molecular weight protein tyrosine phosphatase.
Maccari R; Ottanà R; Ciurleo R; Paoli P; Manao G; Camici G; Laggner C; Langer T
ChemMedChem; 2009 Jun; 4(6):957-62. PubMed ID: 19288492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
